Importantly, the authors detected a high level of circ‐ZNF609 expression in clinical samples from patients with diabetes, hypertension and coronary artery disease, suggesting that targeted regulation of circ‐ZNF609 expression is a potential approach for the treatment of vascular dysfunction. Here, ZNF609 is linked to diabetes mellitus.